Nectero Medical is a clinical-stage biotech company pioneering novel therapies with a potential to treat aneurysmal disease and improve patients’ lives.
The company is led by a highly accomplished, multidisciplinary management team with input from an experienced board of directors and renowned physician leaders in vascular surgery and interventions. Learn More
Abdominal aortic aneurysms (AAA) represent a significant public health concern:
- Current surgical or endovascular treatments are reserved for AAA larger than 5.5cm (5.0cm in women) in diameter, in symptomatic patients, or in rapidly expanding aneurysms
- Smaller AAAs are traditionally monitored with serial ultrasound or computed tomography (CT) surveillance
Nectero Medical is developing an investigational treatment
with the potential to stabilize growth and minimize risk of
rupture of small to mid-sized AAA
Nectero Endovascular Aneurysm Stabilization Treatment (Nectero EAST®) uses an endovascular approach to deliver a proprietary mixture to the site of the aneurysm.
Treatment with the Nectero EAST® System may prevent or significantly delay the need for major intervention. By minimizing further degradation of the aneurysm and strengthening the aortic tissue around the aneurysm, many patients can live out their normal life span and never need to face the challenges of endovascular repair (EVAR) or open surgery to address their aneurysm. Learn More